74 related articles for article (PubMed ID: 33092566)
21. Characteristics of Respiratory Syncytial Virus Infection in Hospitalized Children Before and During the COVID-19 Pandemic in Thailand.
Chaiut W; Sapbamrer R; Dacha S; Sudjaritruk T; Parwati I; Sumarpo A; Malasao R
J Prev Med Public Health; 2023 May; 56(3):212-220. PubMed ID: 37287198
[TBL] [Abstract][Full Text] [Related]
22. RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study.
Xu R; Fathima P; Strunk T; de Klerk N; Snelling TL; Richmond PC; Keil AD; Moore HC
BMC Pediatr; 2020 Oct; 20(1):490. PubMed ID: 33092566
[TBL] [Abstract][Full Text] [Related]
23. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
24. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
25. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants.
Stiboy E; Chan M; Islam MS; Saravanos GL; Lui K; Jaffe A; Homaira N
Pediatr Pulmonol; 2023 Apr; 58(4):1210-1220. PubMed ID: 36748923
[TBL] [Abstract][Full Text] [Related]
26. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
Moore HC; de Klerk N; Richmond PC; Fathima P; Xu R; Keil AD; Snelling TL; Strunk T
J Pediatr; 2019 Nov; 214():121-127.e1. PubMed ID: 31378522
[TBL] [Abstract][Full Text] [Related]
29. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.
Mazur NI; Higgins D; Nunes MC; Melero JA; Langedijk AC; Horsley N; Buchholz UJ; Openshaw PJ; McLellan JS; Englund JA; Mejias A; Karron RA; Simões EA; Knezevic I; Ramilo O; Piedra PA; Chu HY; Falsey AR; Nair H; Kragten-Tabatabaie L; Greenough A; Baraldi E; Papadopoulos NG; Vekemans J; Polack FP; Powell M; Satav A; Walsh EE; Stein RT; Graham BS; Bont LJ;
Lancet Infect Dis; 2018 Oct; 18(10):e295-e311. PubMed ID: 29914800
[TBL] [Abstract][Full Text] [Related]
30. Improving the prescribing of palivizumab.
Trist S; Horsley E; Katf H; Tasker N; Mostaghim M
J Paediatr Child Health; 2018 Dec; 54(12):1353-1356. PubMed ID: 29863814
[TBL] [Abstract][Full Text] [Related]
31. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.
Shi T; McAllister DA; O'Brien KL; Simoes EAF; Madhi SA; Gessner BD; Polack FP; Balsells E; Acacio S; Aguayo C; Alassani I; Ali A; Antonio M; Awasthi S; Awori JO; Azziz-Baumgartner E; Baggett HC; Baillie VL; Balmaseda A; Barahona A; Basnet S; Bassat Q; Basualdo W; Bigogo G; Bont L; Breiman RF; Brooks WA; Broor S; Bruce N; Bruden D; Buchy P; Campbell S; Carosone-Link P; Chadha M; Chipeta J; Chou M; Clara W; Cohen C; de Cuellar E; Dang DA; Dash-Yandag B; Deloria-Knoll M; Dherani M; Eap T; Ebruke BE; Echavarria M; de Freitas Lázaro Emediato CC; Fasce RA; Feikin DR; Feng L; Gentile A; Gordon A; Goswami D; Goyet S; Groome M; Halasa N; Hirve S; Homaira N; Howie SRC; Jara J; Jroundi I; Kartasasmita CB; Khuri-Bulos N; Kotloff KL; Krishnan A; Libster R; Lopez O; Lucero MG; Lucion F; Lupisan SP; Marcone DN; McCracken JP; Mejia M; Moisi JC; Montgomery JM; Moore DP; Moraleda C; Moyes J; Munywoki P; Mutyara K; Nicol MP; Nokes DJ; Nymadawa P; da Costa Oliveira MT; Oshitani H; Pandey N; Paranhos-Baccalà G; Phillips LN; Picot VS; Rahman M; Rakoto-Andrianarivelo M; Rasmussen ZA; Rath BA; Robinson A; Romero C; Russomando G; Salimi V; Sawatwong P; Scheltema N; Schweiger B; Scott JAG; Seidenberg P; Shen K; Singleton R; Sotomayor V; Strand TA; Sutanto A; Sylla M; Tapia MD; Thamthitiwat S; Thomas ED; Tokarz R; Turner C; Venter M; Waicharoen S; Wang J; Watthanaworawit W; Yoshida LM; Yu H; Zar HJ; Campbell H; Nair H;
Lancet; 2017 Sep; 390(10098):946-958. PubMed ID: 28689664
[TBL] [Abstract][Full Text] [Related]
32. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.
French CE; McKenzie BC; Coope C; Rajanaidu S; Paranthaman K; Pebody R; Nguyen-Van-Tam JS; ; Higgins JP; Beck CR
Influenza Other Respir Viruses; 2016 Jul; 10(4):268-90. PubMed ID: 26901358
[TBL] [Abstract][Full Text] [Related]
33. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
34. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis.
Stewart DL; Ryan KJ; Seare JG; Pinsky B; Becker L; Frogel M
BMC Infect Dis; 2013 Jul; 13():334. PubMed ID: 23870086
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
